US equities |
SPCX $167.72 ▲+5.51% NVDA $236.56 ▲+1.12% MU $1,067.15 ▼-0.72% TSLA $378.83 ▲+2.22% MSFT $526.21 ▲+1.68% SNDK $1,710.65 ▼-0.54% INTC $117.10 ▼-1.87% META $745.00 ▲+2.32%
FinancialContent

Skinvisible Inc (OP:SKVI)

0.2026 +0.0005 (+0.25%)
Delayed Quote Updated: 10:59 AM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Skinvisible Inc

News headline image
Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies
Via ACCESS Newswire
News headline image
Skinvisible Announces Article Highlighting Its Proprietary Transdermal Obesity Formulation Development
Via ACCESSWIRE
News headline image
Promising Data on Transdermal Obesity Formulations Announced by Skinvisible
Via ACCESSWIRE
News headline image
Skinvisible Unveils Promising Data on Transdermal Obesity Formulations
Via ACCESSWIRE
News headline image
Skinvisible Expands Obesity Patent Application for Transdermal Delivery
Via ACCESSWIRE
News headline image
Skinvisible Submits Innovative Obesity Patent for Advanced Transdermal Treatment
Via ACCESSWIRE
News headline image
Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome
Via ACCESSWIRE
News headline image
Why Are Quoin Pharma Shares Trading Higher Today? ↗
 
Via Benzinga
News headline image
Skinvisible Announces First Invisicare Delivery Technology Product to Receive U.S. FDA Acceptance of Investigational New Drug
LAS VEGAS, NV / ACCESSWIRE / June 6, 2022 / Skinvisible, Inc. ("Skinvisible") (OTCQB:SKVI), is pleased to announce that its licensee Quoin Pharmaceuticals, Inc. ("Quoin") (NASDAQ:QNRX), has received... 
From Skinvisible Inc
Via AccessWire